The problem we solve: Pulmonary fibrosis is a debilitating, chronic disease that can be caused by Covid-19. There is currently no treatment for this lasting consequence of moderate to severe Covid-19 infection
About our solution: We have developed RT1840 as an aerosolized treatment for delivery into damaged lungs. Our data show a profound reversal of lung damage with RT1840 therapy This compound has an outstanding safety profile in humans.Progress to date:
Creator: David Weinstein
Location: New York
Bio: Neurologist and Neuroscientist; former Professor in the Departments of Neuroscience, Neurology, Pathology and the Comprehensive Cancer Center at the Albert Einstein College of Medicine and Adjunct Associate Professor of Pathology, Columbia College of Physicians and Surgeons Seasoned biotech executive, with C-suite experience at InteKrin Therapeutics, GliaMed Therapeutics, RiverTown Therapeutics, Androbiosciences MS (Pharmacology), MD, and PhD from NYU and Columbia College of Physicians and Surgeons
Title: Chief Executive Officer
Advanced Degree(s): MD, PHD
COVID Problem We Address
Pulmonary fibrosis is a debilitating, chronic disease that can be caused by Covid-19. Based on early data, it is eatimated that up to 80% of moderate to severe Covid patients will suffer from lung scarring. There is currently no treatment for this lasting consequence of moderate to severe Covid-19 infection. We believe that RT1840 has the possibility to give Covid-19 patients the ability to ameliorate the lasting effects of the virus-induced lung damage.
Our COVID Solution
We believe that RT1840 has the possibility to give Covid-19 patients the ability to ameliorate the lasting effects of the virus-induced lung damage, and thus return them to a fuller, more active and interactive life.
- Estimated that 40-70% of the worlds population will be infected with COVID-19
- Early reports suggest that up to 70% to 80% of moderately to severly affected Covid-19 patients will have residual pulmonary disease and fibrosis. This is a huge and unmet market
Projected 3 Year Growth
We seek to either co develop or license RT1840 to a larger biotech or pharma company.
RT1840 will be a prescription drug. As such, we anticipate that the salesforce will call on pulmonologists, critical care, infectious disease specialists and internal medicine physicians.
There currently is no effective treatment for pulmonary fibrosis. To the best of our understanding, there are no treatments in development to reverse Covid-19 induced lung scarring
We have been in ongoing discussions with a number of potential equity and strategic partners
Please note that access to the company's confidential materials is limited. Click this button to request access from the Company and its representatives.
No updates found .
Help us find best new ideas to fund by telling us what you think. Your feedback goes straight to the team behind this project in private, so tell them what you really think.